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Central nervous systemtion can cause a self-limiting disease (dengue fever) or a more severe clinical
presentation known as dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS). Furthermore, data
from recent dengue epidemics in Brazil indicate that the neurological manifestations are becoming more
prevalent. However, the neuropathogenesis of dengue are not well understood. The balance between viral
replication efﬁciency and innate immunity — in opposition during the early stages of infection — determines
the clinical outcome of DENV infection. In this study, we investigated the effects of DENV infection on the
transcription proﬁle of the central nervous system (CNS) of mice. We observed in infected mice the up-
regulation of 151 genes possibly involved in neuropathogenesis of dengue. Conversely, they may have a
protective effect. Ingenuity Systems software analysis demonstrated, that the main pathways modulated by
DENV infection in the mouse CNS are involved in interferon signaling and antigen presentation.
© 2008 Elsevier Inc. All rights reserved.IntroductionDengue is a mosquito-borne ﬂavivirosis caused by four dengue
virus serotypes (DENV1, 2, 3 and 4). It is epidemic in tropical and
subtropical regions around the world. DENV infections have become a
major international public health concern (Gubler, 1997) in recent
years. The World Health Organization (WHO) estimates that at least
2.5 billion people are at risk of contracting dengue and the number of
infections worldwide may reach 10 million cases per year (Clyde et al.,
2006;WHO, 2002). In Brazil, more than 4million cases of dengue have
been recorded since its re-introduction in 1986 (SVS, 2007).
DENV1, 2, 3 and 4 are from the Flaviviridae family. Infection with
any of these serotypes can cause dengue fever (DF), a self-limiting
disease, or dengue hemorrhagic fever/dengue shock syndrome (DHF/
DSS), characterized by vascular permeability and abnormal home-
ostasis (Halstead, 1988). The mechanisms involved in the progression
of a certain proportion of cases to severe disease are not completely
understood. DHF/DSSmay develop as a result of immune sensitizationSantos).
ed equally to this study.
l rights reserved.from prior DENV infection (Halstead and O'Rourke, 1977) or possibly
through a cytokine-mediated process of plasma leakage, involving
interactions between DENV-infected monocytes/macrophages and
memory CD4+ and CD8+ DENV-reactive T cells (Pang et al., 2007;
Rothman, 2003; Kurane et al., 1990). Recently, Luplertlop et al. (2006)
demonstrated that immature dendritic cells infected with DENV2
overproduce a metalloproteinase 9 and 2 (MMP-9 and MMP-2) in a
viral dose-dependent manner. MMP-9 and MMP-2 seem to enhance
endothelial permeability, by reducing the expression levels of genes
encoding platelet endothelial adhesion molecule 1 (PECAM-1) and
vascular endothelium (VE)-cadherin cell adhesion molecules, causing
the redistribution of F-actin ﬁbers. Thus, production of these protein-
ases could contribute to the pathogenesis of DHF.
During epidemic peaks, approximately 80% of dengue cases seem to
be asymptomatic or produce mild disease symptoms, suggesting that
innate immunity can neutralize the DENV infection (Navarro-Sánchez
et al., 2005). DENV replication during the early stages of infection may
determine clinical outcomes; thus, it is important to understand the
impact of dengue virus infection on the host innate immunity. Until
recently, innate immunity was considered to be a semi-obsolescent
hold-over from invertebrate immunity that has been largely super-
seded by the acquired (adaptive) immune system of vertebrates.
Fig.1. Viral load in mouse brain infectedwith DENV1. Viral load in the CNS of Swiss mice
infected with 8000 C6/36 ffu of DENV1 at 5, 6, 7 and 8 days post-infection (dpi). Levels
of viral RNAwere normalized using GAPDHmRNA. Mock-infected animals (♦) and FGA/
89 infected animals (■).
320 J. Bordignon et al. / Virology 377 (2008) 319–329However, it has becomeapparent that the innate and acquired immune
systems cooperate to create an effective anti-microbial immune
response (Fearon, 1999). Additionally, innate immunity is important
in shaping the adaptive immune response, and has anti-cancer and
immunomodulatory activities (Delhaye et al., 2006).
Early activation of natural killer (NK) cells and interferon-dependent
immunity (IFN) may be also important in limiting viral replication
during the ﬁrst stages of DENV infection. Thus, the varying ability of
DENVstrains to overcome the innate immunitymayunderlie differences
observed in their virulence (Navarro-Sánchez et al., 2005; Shresta et al.,
2004). Additionally, genetic polymorphisms in IFN-stimulated genes
(ISGs)may account for differences between hosts in the capacity to ﬁght
against infection (Knapp et al., 2003). Currently there is no speciﬁc
therapy or vaccine available for DF or DHF/DSS. Therapies targeting the
innate immunity may be of interest in addressing this issue (Rothman,
2004).Fig. 2. Immunohistochemical analysis showing DENV1 antigen in brain sections frommock-in
cortex and hippocampus, respectively, of mock-infected animals. Panel B: Section of the temp
absence of antigen-positive cells in the acellular layer (a) (rich in axons and dendrites from ne
(black arrows) in the sequential layer (s), which is composed of temporal neuronal cells. An
Panel C: Enlargement of the sequential layer of the temporal cortex section shown in panel B
(arrow head). Panel E: Section of the hippocampus showing some DENV1-antigen-positive
portion of the section of the hippocampus viewed in panel E, showing antigen-positive hippo
were prepared and stained as described in the methods, and images were obtained using an
50 μm.The aim of this study was to evaluate modulation of gene
expression by DENV1 infection in the central nervous system (CNS)
of mice. Our ﬁndings demonstrate a strong induction of ISG mRNAs
with known antiviral activity despite the fact that we did not detect
the production of cytokine transcripts, including IL-8, IL-6, TNF-α, and
IFN-α, β, and g using microarray technology. The pattern of the innate
immunity response in DENV infections may provide new insight into
the immunopathogenesis of dengue and open up new possibilities for
dengue treatment based on immunomodulation.
Results
DENV replication in mice CNS
We previously demonstrated a maximum viral replication activity
for FGA/89 in the mouse central nervous system at 9 dpi (Bordignon
et al., 2007). We analyzed the transcription proﬁle of the CNS in mice at
5, 6, 7 and8dpi—beforemaximumreplication activitywas reached— to
study the early stages of DENV infection. Viral replication activity was
6.1-fold higher on dpi 8 than that on dpi 5 in animals infected with
DENV1 FGA/89 (51.3 viral RNA/GAPDHmRNA on day 5; 313.7 viral RNA/
GAPDH mRNA on 8 dpi) (Fig. 1).
We previously demonstrated that DENV replicates efﬁciently and
produces viable viral particles in murine neuronal primary cell culture
(Bordignon et al., 2007). However, DENV replication in neuronal cells
in man is a controversial issue (Clyde et al., 2006). We performed
immunohistochemical analyses of brain sections from infected
animals to determine the main cellular target for viral replication in
the mouse central nervous system (Fig. 2). Analyses of the temporal
cortex showed that meningeal cells and the acellular layer (rich in
axons and dendrites from neuronal cells and processes from glial cells)
were not infected by DENV1. In contrast, the subsequent layer in thefected and DENV1-infected Swiss mice at 10 dpi. Panel A and D: Sections of the neuronal
oral cortex of DENV1-infected mouse showing absence of meningeal cells (arrow head),
uronal cells and processes of glial cells), and presence of numerous antigen-positive cells
tigen-positive cells were also not observed in deeper layers (p) of the temporal cortex.
revealing the DENV1-infected neuronal cells (black arrow) and non-infected astrocytes
cells (black arrows) in the region of hipocampal neurons (h). Panel F: Enlargement of a
campus neuronal cells (black arrow) and non-infected astrocytes (arrow head). Sections
Olympus BX 50 with Image-Pro® Plus software version 4.5 (Maryland). Scale bars are
Fig. 3. Microarray experimental design. Numbers 1–8 represent the number of
hybridization experiments performed to analyze and compare the gene expression
proﬁles from DENV1-infected mice mock-infected animals. Arrows indicate staining
with Cy3 to Cy5 (Cy3 → Cy5).
321J. Bordignon et al. / Virology 377 (2008) 319–329neuronal cortex contained numerous DENV antigen-positive cells,
particularly in the temporal neuronal cell layers (Fig. 2B). We also
observed DENV antigen in neuronal cells in the hippocampus, but no
viral antigen was detected in white matter using the 4G2 monoclonal
antibody (Fig. 2E). Despite our inability to detect viral antigen in
astrocytes and oligodendrocytes in the temporal cortex, we cannot
exclude the possibility that these cells are targets for DENV1 repli-
cation in the mouse CNS (Fig. 2).
Host transcription proﬁle after dengue virus replication
The microarray used in this study encompasses the whole mouse
genome, and the hybridizations performed are depicted in Fig. 3. Data
from DENV1- andmock-infected animals were compared at each time
point as described above, and 151 genes were thus selected (Table 2).
Overall, the largest difference in transcription levels between the
mock and DENV-infected groups was detected at 8 days post-
infection, corresponding to the time of maximum viral replication
activity (313.7 viral mRNA/GAPDH mRNA). Thus, gene modulation
seems to correlate with viral replication.
Major pathways modulated by DENV infection in the mouse CNS
Wedetermined themajor gene induction pathways involved in the
response to DENV1 infection of the mouse CNS, by analyzing the 151Fig. 4. Functional annotations associated with the 151 selected genes. The microarray data
biological functions and the y-axis the statistical signiﬁcance (expressed as p-value, with a
speciﬁc dataset would be if it was only due random chance. Ratio is calculated by taking the n
the total number of genes in that Canonical Pathway. JAK/Stat: Janus Kinase/Signal Trans
Stimulator Factor; PDGF: Platelet-derived Growth Factor.selected genes with Ingenuity® Systems software. We found that the
main pathways modulated during the infection are those related to
the immune response; for example, IFN signaling and antigen
presentation (Fig. 4) had the lowest p-values (8.96×10−16 and
9.19×10−14, respectively). Genes for a number of transcription factors,
including signal transducer and activator of transcription 1 and 2
(Stat1 and Stat2), IFN-dependent positive acting transcription factor 3
(Isgf3g or Irf9) and the IFN regulatory factors 1 and 7 (Irf1 and Irf7),
were up-regulated in DENV1-infected mice, demonstrating activation
of the IFN-signaling pathway in mice CNS.
Mostof theup-regulatedgenes fromthe IFN-signalingpathwaywere
ISGs. ISGs encode proteins with antiviral activity; for example, the 2′–5′
oligoadenylate synthetase gene family (Oas1b, Oas1g, Oasl1, Oasl2, Oas1a
and Oas2) which is involved in conferring resistance to West Nile virus
(WNV) infection (Kajaste-Rudnitski et al., 2006). Another family of ISG
genes that were up-regulated (3.2–49.2 fold) encode IFN-induced
proteins with tetratricopeptide repeats (TPR motifs), known as the P56
protein family (Iﬁt1, 2 and 3) (Table 2; Fig. 5). The TPR motif is a
degenerate, 34-amino acid protein–protein interactionmodule found in
multiple copies in a number of functionally distinct proteins that
facilitate speciﬁc interactions with partner proteins (Blatch and Lassle,
1999; D'Andrea and Regan, 2003; Lamb et al., 1995). Interaction of P56
with one such target, the translation initiation factor 3 (eIF3), leads to
translation inhibition (Sarkar et al., 2005). A third major group of ISG
genes stimulated in infected mice encodes the IFN-inducible double-
stranded RNA-dependent protein kinase (Prkr or Eif2ak2) family. These
proteinsphosphorylate theeukaryotic translation factor eIF2α, arresting
protein synthesis (Meurs et al., 1992).
Other IFN-stimulated genes represented in CNS of infectedmice are
those involved in antigen processing and presentation— immunopro-
teasome assembly (Psmb8 and Psmb9), transportation of processed
antigen to endoplasmic reticulum (Tap1 and Tap2) and presentation of
antigen on the cell surface by major histocompatibility molecules
(MHC) class I (H2-T9, H2-T10, H2-T22, H2-T23, H2-K1, H2-Q2, H2-Q6, H2-
Q7, H2-Q8, and H2-L) — were also up-regulated in DENV1-infected
mice (Table 2; Fig. 5), as were MHC class II molecules, like H2-Ea.
Real time PCR analyzes of modulated genes
We performed qPCR assays for 10 genes (Stat1, Irf7, Irf1, Iﬁt3, Gbp4,
Mx1, Oas1b, Ccl5, Psmb8 and Tap1) to conﬁrm the gene expression
data obtained from the microarrays. Primers used are listed in Table 1.were analyzed using Ingenuity Pathways Analysis System. The x-axis displays selected
0.05 threshold). The p-value measures how likely the observed association between a
umber of genes from dataset that participates in a Canonical Pathway, and dividing it by
ducer and Activator of Transcription; GM-CSF: Granulocyte and Macrophage Colony
Fig. 5. Comparison of gene modulation levels measured by microarray analysis and qPCR. Comparison of levels of fold increase in gene expression of Stat1, Irf1, Irf7, Iﬁt3, Gbp4, Mx1,
Oas1b, Ccl5, Psmb8 and Tap1, measured by microarray (white bars) and qPCR (black bars).
322 J. Bordignon et al. / Virology 377 (2008) 319–329The genes, Stat1, Irf1 and Irf7, were selected because of their crucial role
in IFN response after virus infection (Honda et al., 2005a,b). The IFN-
stimulated genes, Oas1b, Gbp4,Mx1, Ccl5, Iﬁt3, Tap1 and Psmb8 that aregenes involved in antiviral response and in antigen processing and
presentation byMHC class I, were also included in qPCR analysis. mRNA
levels detected by qPCR were consistent with microarray data for the
Table 1
Selected primers for qPCR, GenBank GeneID and expected molecular weight of amplicon
Gene GenBank GeneID Forward primer Reverse primer Amplicon
Stat1 20846 GAACGCGCTCTGCTCAA TGCGAATAATATCTGGGAAAGTAA 190 bp
Irf7 54123 GCCAGGAGCAAGACCGTGTT TGCCCCACCACTGCCTGTA 166 bp
Irf1 16362 TGTGTCGTCAGCAGCAGTCTCT GTCTTCGGCTATCTTCCCTTCCT 153 bp
Iﬁt3 15959 CTGAAGGGGAGCGATTGATT AACGGCACATGACCAAAGAGTAGA 182 bp
Oas1b 23961 TTCTACGCCAATCTCATCAGTG GGTCCCCCAGCTTCTCCTTAC 172 bp
Mx1 17857 AACCCTGCTACCTTTCAA AAGCATCGTTTTCTCTATTTC 183 bp
Gbp4⁎ 17472 TGGGGGACACAGGCTCTACA GCCTGCAGGATGGAACTCTCAA 144 bp
Ccl5 20304 GTGCCCACGTCAAGGAGTATTTCT TGGCGGTTCCTTCGAGTGACAA 82 bp
Tap1 21354 GTGGCCGCAGTGGGACAAGAG AGGGCACTGGTGGCATCATC 278 bp
Psmb8 16913 TGATGCTGCAGTACCGGGGGATGG TAGCTCTGCGGCCAAGGTCGTAGG 222 bp
IFN-β 15977 CGCTGCGTTCCTGCTGTG GATCTTGAAGTCCGCCCTGTAG 154 bp
IFN-α⁎⁎ 15964 GACTCATCTGCTGCTTGGAATGCAACCCTCC GACTCACTCCTTCTCCTCACTCAGTCTTGCC 294 bp
⁎ Annealing temperature 65 °C.
⁎⁎ Primer sequence described by Olson et al. (2001).
323J. Bordignon et al. / Virology 377 (2008) 319–329selected genes, although there were notable differences in the extent of
gene induction measured by the array and qPCR methods (Fig. 5).
While a signiﬁcant expression of IFN-stimulated genes was
observed by microarray experiments, the up-regulation of IFN-α
and -β transcripts was not detect. When qPCR analyzes of both genes
were performed, the expression of IFN-β gene in DENV-infected mice
was detected, compared to mock-infected animals, with a fold
increase varying from 1.1 to 2.8, between days 5 and 8 post-infection
(dpi). The IFN-α mRNA was not detected (data not shown).
Discussion
The clinical outcome of a viral infection is largely dependent on the
balance between host response and viral replication rates. The ability
of the virus to evade the host immune response is crucial to the
development of disease in a susceptible host. Upon detection of viral
infection, cells initiate a rapid antiviral response mediated by IFN and
other cytokines that prevent the spread of the infection (Pasieka et al.,
2006). Certain cellular proteins, including the toll-like receptors (TLRs)
and other pattern-recognition receptors (PRRs), act as sensors and
recognize dsRNA and other pathogen-associated molecular patterns
(PAMPs), leading to IFN production which can then activate the IFN-
response pathway, and creates an antiviral state in infected, as well as
surrounding cells (Shaw and Palese, 2005). Shresta et al. (2004)
demonstrated that IFN-α/β receptor-mediated action limits initial
DENV replication in mouse extraneural sites and controls subsequent
viral spread into the central nervous system.
We studied the gene transcription proﬁle of mouse CNS infected
with DENV1, to further contribute to the knowledge of dengue–
vertebrate host interactions. The major pathways affected by DENV1
infection in the CNS of mice were those involved in IFN signaling,
antigen presentation and processing, the complement cascade, and
ubiquitination (Fig. 4). These changes are consistent with a robust
innate immune response characterized in particular by genes induced
by type I IFN (IFN-α/β). Our data are consistent with a previous study
of peripheral blood mononuclear cells (PBMC) from rhesus monkeys,
which demonstrated a profound up-regulation of ISGs following
DENV1 infection (Sariol et al., 2007). Warke et al. (2008) have also
recently demonstrated the expression of ISGs with known antiviral
activity in human umbilical vein endothelial cells (HUVEC), mono-
cytes and B cells that have been isolated from healthy volunteers and
infected with DENV2. We observed a similar activation of the IFN-
signaling pathway-induced gene expression following DENV1 infec-
tion of the CNS of mice (Table 2). The mechanisms involved in the
antiviral activity remain unknown for most IFN-inducible proteins,
one major role of these molecules is to reduce the activity of host
enzymatic machinery, thus reducing viral replication, preventing
infection of neighboring uninfected cells, and giving time for the host
to arm an adaptive immune response.Although the modulations in IFN-α/β genes were not detected in
the microarrays experiments, the expression of IFN-β, but not IFN-α,
could be quantiﬁed by qPCR. A possible explanation for the lack of
modulation in IFN-α/β in themicroarrays experiments could be due to
the approach of using whole tissue instead cell culture systems.
Changes in mRNA expression patterns in response to viruses that
infected the nonrenewable cell populations of CNS may, however, be
better studied in the intact host rather than in cell cultures (Venter
et al., 2005). Other important point concerning IFN-α is the fact that it
ismodulated very early during viral infections,which could explain the
negative result by qPCR.Moreover, low levels of IFN-α/β are capable to
induce very strong ISGs stimulation as demonstrated in several
microarray experiments (Bourne et al., 2007; Johnston et al., 2001;
Sariol et al., 2007). Additionally, other authors had found the
expression of ISGs in chimpanzee liver cells chronically infected with
hepatitis C virus (Bigger et al., 2004) and in monkey PBMCs infected
withDENV1 (Sariol et al., 2007),without detecting IFN-α/β transcripts.
In particular, one major ISG family up-regulated in the CNS of
DENV1-infected mice encodes the 2′–5′ oligoadenylate system (2′–5′
OAS), which activates RNase L, inducing RNA degradation and
reducing viral replication efﬁciency. It was shown that 2′–5′OAS
genes confer resistance to infection with ﬂaviviruses like hepatitis C
virus (HCV) (Knapp et al., 2003), WNV (Kajaste-Rudnitski et al., 2006;
Venter et al., 2005) and DENV (Warke et al., 2003). Resistance
phenotype for ﬂavivirus-induced disease in mice suggested that this
phenotype was controlled by an autosomal dominant allele (Flvr), that
was identiﬁed as the 2′–5′OAS 1b (Oas1b). Susceptible mice show a
premature stop codon, producing a protein lacking 30% of the C-
terminal sequence as compared with the resistance counterpart
(Perelygin et al., 2002). Scherbik et al. (2007) demonstrated that the
knock-in of the Oas1br allele, which recovered the C-terminal region
in susceptible mice, resulting in a resistant phenotype. Recently,
Malathi et al. (2007) demonstrated that 2′–5′OAS activates RNase L,
that produces small RNA cleavage products from self- or viral-RNA
that induces the production of IFN-β through a pathway involving
activation of retinoic acid-inducible gene-I (RIG-I), melanoma differ-
entiation associated gene-5 (MDA5), and their interaction protein IPS1
(IFN-β promoter stimulator protein-1). The results demonstrated that
OAS/RNase L has an effect on innate signaling pathways, enhancing
IFN-β production, what could represent an interesting approach to the
development of new antiviral therapies (Malathi et al., 2007).
Other antiviral ISG genes up-regulated in the CNS ofmice following
DENV1 infection include members of the Myxovirus protein family
(Mx). In our hands, mouse CNS over-expressed Mx1 (3.9–11.3 fold in
microarray experiments and 5.8–36.5 in qPCR assays) and Mx2 (6.9–
20.0 fold in microarray experiments). It was recently shown that mice
with deletion of the Mx1 gene (Mx1−/−) are susceptible to infection
with inﬂuenza virus H5N1 and 1918 pandemic inﬂuenza virus,
whereas a high level of resistance was observed in Mx1(+/+) mice
Table 2
Selected genes up-regulated in brain tissue collected following DENV-1 infected mice
General
Function
Speciﬁc Function Biological Process Gene Symbol Entrez
GeneID
Description 5 dpi 6 dpi 7 dpi 8 dpi
Immune
response
Transcription Interferon type I
biosynthetic process
Irf9 16391 Interferon dependent positive acting transcription
factor 3 gamma
3.52 5.59 4.6 4.68
Irf7 54123 Interferon regulatory factor 7 3.01 5.24 3.9 4.99
Irf8 15900 Interferon regulatory factor 8 2.21 1.88 3.05 8
Cytokine and
chemokine signalling
Stat1 20846 Signal transducer and activator of transcription 1 7.98 16.6 12.6 13.7
Stat2 20847 Signal transducer and activator of transcription 2 1.62 4.78 2.68 5.36
Nmi 64685 N-myc (and Stat1) interactor 2.78 3.47 2.4 3.8
Positive regulator of
interleukin-12
Irf1 16362 Interferon regulatory factor 1 3.23 2.55 1.79 7.12
PML body Pml 18854 Promyelocytic leukemia 1.97 2.3 2.23 2.13
Sp100 20684 Nuclear antigen Sp100 3.03 3.38 1.72 2.86
Endopeptidase Antigen presentation Psmb8 16913 Proteosome (prosome, macropain) subunit, beta type 8
(large multifunctional protease 7)
4.03 6.51 4.68 10.8
Psmb9 16912 Proteosome (prosome, macropain) subunit, beta type 9
(large multifunctional protease 2)
3.96 6.56 2.43 14.3
Transport Antigen presentation Tap1 21354 Transporter 1, ATP-binding cassette, subfamily B
(MDR/TAP)
2.99 4.42 2.64 6.59
Tap2 21355 Transporter 2, ATP-binding cassette, subfamily B
(MDR/TAP)
3.59 2.75 2.84 13.1
Antigen binding Antigen presentation Lilrb4 14728 Leukocyte immunoglobulin-like receptor, subfamily B,
member 4
3.08 1.71 1.18 3.51
MHC class II
presentation
Antigen presentation H2-Ea 14968 Histocompatibility 2, class II antigen E alpha 1.55 2.97 2.3 4.58
H2-Ab1 14961 Histocompatibility 2, class II antigen A, beta 1 3.1 1.45 1.27 7.67
Ctss 13040 Cathepsin S 2.64 2.81 2.98 6.78
Cd74 16149 CD74 antigen (invariant polypeptide of major
histocompatibility complex class II antigen-associated)
1.84 1.53 1.72 3.191
MHC class I
presentation
Antigen presentation H2-Q2 15013 Histocompatibility 2, Q region locus 2 4.38 5.68 2.24 11.2
H2-Q8 15019 Histocompatibility 2, Q region locus 8 3.4 3.88 2.47 5.53
H2-Q7 15018 Histocompatibility 2, Q region locus 7 3.2 5.67 3.57 6.31
H2-Q6 110557 Histocompatibility 2, Q region locus 6 2.81 5.25 3.43 7.32
H2-Q5 15016 Histocompatibility 2, Q region locus 5 2.59 1.86 2.05 4.65
H2-L 14980 Histocompatibility 2, D region 3.69 5.99 3.75 12.5
H2-T9 15051 Histocompatibility 2, T region locus 9 3.86 2.34 2.43 5.07
H2-T10 15024 Histocompatibility 2, T region locus 10 5.94 3.65 2.59 6.34
H2-T22 15039 Histocompatibility 2, T region locus 22 3.74 2.34 2.12 5.09
H2-T23 15040 Histocompatibility 2, T region locus 23 4.24 5.48 2.63 8.09
H2-K1 14973 Histocompatibility 2, K1, K region 5.06 6.41 3.69 12.22
B2m 12010 Beta-2 microglobulin 4.79 6.28 4.36 11.3
GTP binding Interferon-induced Gbp1 14468 Guanylate nucleotide binding protein 1 4.41 1.46 1.59 9.57
Gbp2 14469 Guanylate nucleotide binding protein 2 7.97 6.7 3.63 27.6
Gbp4 17472 Guanylate nucleotide binding protein 4 3.82 6.81 3.48 12.99
Gbp5 229898 Guanylate nucleotide binding protein 5 2.17 1.51 1.71 4.6
Irgm 15944 Immunity-related GTPase family, M 8.86 11.5 7.48 12.4
Gbp6 229900 Guanylate nucleotide binding protein 6 4.39 8.21 3.57 9.92
BC057170 236573 cDNA sequence BC057170 3.56 2.49 3.09 7.44
Mpa2l 100702 Macrophage activation 2 like 8.89 9.13 8.1 30.3
RNA binding Interferon-induced Oas1b 23961 2′-5′oligoadenylate synthetase 1B 7.25 11.3 8.79 12.5
Oas1g 23960 2′-5′oligoadenylate synthetase 1G 8.23 13.7 9.24 14.6
Oasl1 231655 2′-5′oligoadenylate synthetase-like 1 3.84 7.16 2.86 9.03
Oasl2 23962 2′-5′oligoadenylate synthetase-like 2 5.91 15.2 10.1 13.7
Oas1a 246730 2′-5′oligoadenylate synthetase 1A 2.11 4.33 2.23 4.21
Oas2 246728 2′-5′oligoadenylate synthetase 2 2.6 2.94 1.79 5.19
DNA binding Interferon-induced Sp110 109032 Sp110 nuclear body protein 3.04 2.75 2.37 5.79
Binding Interferon-induced Iﬁt1 15957 Interferon-induced protein with tetracopeptide repeats 1 8.82 23.7 12.4 37.6
Iﬁt2 15958 Interferon-induced protein with tetracopeptide
repeats 2
3.28 4.54 4.51 6.53
Iﬁt3 15959 Interferon-induced protein with tetracopeptide
repeats 3
15.4 37 14.8 49.2
Helicase Interferon-induced Iﬁh1 71586 Interferon induce with helicase C domain 1 6.34 9.32 4.73 12.8
Interferon type I
biosynthetic process
Dhx58 230073 DEXH (Asp-Glu-X-His) box polypeptide 58 4.57 6.67 4.44 7.97
Ddx58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 4 6.35 4.27 6.43
Protein binding NC Iﬁ203 15950 Interferon activated gene 203 2.47 2.85 2.56 7.44
Interferon-induced Pyhin1 236312 Pyrin and HIN domain family, member 1 6.45 1.48 1.93 11.25
Apoptosis Bcl2a1a 12044 B-cell leukemia/lymphoma 2 related protein A1a 2.32 1.87 2.2 3.91
NC NC Iﬁ205 15952 Interferon activated gene 205 5.12 5.45 6.41 25.2
Apoptosis Bcl2a1b 12045 B-cell leukemia/lymphoma 2 realted protein A1b 3.09 1.97 1.89 3.15
Bcl2a1c 12046 B-cell/leukemia/lymphoma 2 related protein A1c 3.28 1.41 1.75 7.93
Receptor Interferon-induced Iﬁtm1 68713 Interferon-induced transmembrane protein 1 3.09 5.72 2.38 7.59
Iﬁtm2 80876 Interferon-induced transmembrane protein 2 2.34 4.39 2.25 5.8
Iﬁtm3 66141 Interferon-induced transmembrane protein 3 4.29 8.23 5.34 14.3




Speciﬁc Function Biological Process Gene Symbol Entrez
GeneID
Description 5 dpi 6 dpi 7 dpi 8 dpi
Immune
response
Receptor Cell adhesion Lgals9 16859 Lectin, galactose binding, soluble 9 3.46 4.02 4.47 5.46
Lgals3bp 19039 Lectin, galactosidase-binding, soluble, 3 binding protein 6.98 7.13 7.29 11.4
Icam1 15894 Intercellular adhesion molecule 1 1.91 1.52 1.47 3.91
Itgb2 16414 Integrin beta-2 1.74 1.51 1.74 3.06
Siglec1 20612 Sialic acid binding Ig-like lectin 1, sialoadhesin 1.44 2.56 3.58 4.46
B-cell activation Bst2 69550 Bone marrow stromal cell antigen 2 7.58 14 8.75 16.8
Cell proliferation Cd274 60533 CD274 antigen 4.87 1.84 1.89 9.12
Inhibition of
proinﬂamatory cytokines
Il10ra 16154 Interleukin 10 receptor, alpha 1.93 2.79 1.71 3.68
NC Ly6e 17069 Lymphocyte antigen 6 complex, locus E 2.16 3.92 2.3 5.33
GTPase Interferon-induced Igtp 16145 Interferon gamma induced GTPase 8.15 6.5 5.75 23.9
Mx1 17857 Myxovirus (inﬂuenza virus) resistance 1 3.97 4.34 2.75 11.3
Mx2 17858 Myxovirus (inﬂuenza virus) resistance 2 6.89 9.61 8.36 20
Gvin1 74558 GTPase, very large interferon inducible 1 2.85 4.01 1.61 4
Iigp2 54396 Interferon inducible GTPase 2 7.43 3.27 3.29 21
Iigp1 60440 Interferon inducible GTPase 1 19.8 19.9 13.6 60.1
Transcription Interferon-induced Iﬁ204 15951 Interferon activated gene 204 5.5 4.06 6.05 19.7
Exonulcease Interferon-induced Isg20 57444 Interferon-stimulated protein 1.38 2.31 1.82 4.2
Kinase Interferon-induced Eif2ak2 19106 Eukaryotic translation initiation factor 2-alpha kinase 2 3.9 7.07 4.36 7.84
Cytokine/chemokine Chemotaxis Ccl5 20304 Chemokine (C-C motif) ligand 5 13.1 9.37 7.33 26.9
Ccl12 20293 Chemokine (C-C motif) ligand 12 3.97 9.89 6.14 23
Cxcl10 15945 Chemokine (C-X-C motif) ligand 10 2.37 2.47 2.84 20.5
Apoptosis Tnfsf10 22035 Tumor necrosis factor (ligand) superfamily, member 10 1.47 2.8 1.86 2.91
Peptidase Complement activation Cfb 14962 Histocompatibility 2, complement component factor B 7.52 5.71 6.61 19.7
C2 12263 Complement component 2 (within H2-S) 2.2 2.42 1.9 5.89
C1r 50909 Complement component 1, r subcomponent 4.52 1.73 2.39 5.62
Peptidase inhibitor Complement activation C4b 12268 Complement component 4B (Childo blood group) 2.69 2.41 2.4 5.08
Endopeptidase
inhibitor
Apoptosis Serpina3g 20715 Serine (or cysteine) proteinase inhibitor, clade A,
member 3G
5.29 1.52 2.83 7.88
NC Complement activation C1qb 12260 Complement component 1, q subcomponent, beta
polypeptide
1.41 1.91 1.91 3.26
Apoptosis Bcl2a1d 12047 B-cell leukemia/lymphoma 2 related protein A1d 2.4 1.58 1.53 3.39
Caspase activity Apoptosis Casp1 12362 Caspase 1 2.88 2.01 2.04 4.84
Poly-A-polymerase NC Parp9 80285 Poly (ADP-ribose) polymerase family, member 9 4.53 6.1 3.32 9.47
Virus response Zc3hav1 78781 Zinc ﬁnger CCCH type, antiviral 1 4.25 3.92 2.38 6.85
Apoptosis IFN-induced Sp110 109032 Sp110 nuclear body protein 1.31 3.95 2.07 4.92
Catalytic activity Virus response Rsad2 58185 Radical S-adenosyl methionine domain containing 2 2.64 2.48 2.03 7.77
IFN-induced Samhd1 56045 SAM domain and HD domain 1 1.78 2.01 1.89 5.65
dTTP biosynthesis LPS response Tyki 22169 Thymidylate kinase family LPS-inducible member 1.2 2.51 1.76 3.73
NC IFN-induced Iﬁ44 99899 Interferon-induced protein 44 7.55 12.8 5.51 16.1
Iﬁ27 76933 Interferon, alpha-inducible protein 27 8.62 6.24 12.9 21
NC Interferon-induced Iﬁ47 15953 Interferon gamma inducible protein 47 9.47 12.4 8.7 38
NC NC Iﬁ202b 26388 Interferon activated 202B 8.29 11.5 8.38 40.1
Plac8 231507 Placenta-speciﬁc 8 15.2 14.1 12.4 33
Defense
response
GPI anchored Cell proliferation Ly6a 110454 Lymphocyte antigen 6 complex, locus A 3.11 2.40 2.38 10.79
NC Ly6c1 56778 Lymphocyte antigen 6 complex, locus C 1.82 2.14 1.62 5.3
Ly6f 17071 Lymphocyte antigen 6 complex, locus F 3.33 1.67 2.7 7.41
Protein binding Cell adhesion Ly9 17085 Lymphocyte antigen 9 2.53 1.69 1.81 3.39
Macrophage
associated
NC Mpeg1 17476 Macrophage expressed gene 1 1.51 2.91 2.3 4.41
Ubiquitin
cycle
Ubiquitin ligase Interferon-induced Dtx31 209200 Deltex 3-like (Drosophila) 3.04 3.73 3.59 4.74
Herc5 67138 Hect domain and RLD5 3.48 4.15 3 6.98
Trim25 217069 Tripartite motif protein 25 3.23 4.52 3.57 4.61
Protein modiﬁcation Ube2l6 56791 Ubiquitin-conjugating enzyme E2L6 1.33 2.08 3.28 2.59
Trim21 20821 Tripartite motif protein 21 3.52 6.72 3.3 9.68
Ubiquitin activating Protein modiﬁcation Ube1l 74153 Ubiqutin-activating enzyme E1-like 1.84 4.32 2.9 5.91
Protein binding Interferon-induced Isg15 53606 ISG15 ubiquitin-like modiﬁer 10.4 22.3 9.41 26.9
Peptidase Interferon-induced Usp18 24110 Ubiquitin speciﬁc protease 18 31.6 18.3 26.9
Signal
transduction
Receptor Apoptosis Tspo 12257 Translocator
protein
1.51 2.06 1.82 2.68
NC Fgl2 14190 Fibrinogen-like protein 2 1.94 1.42 1.67 3.43
Ms4a6d 68774 Membrane-spaning 4-domains, subfamily A,
member 4D
4.92 3.2 2.16 5.11
Ms4a4c 64380 Membrane-spaning 4-domains, subfamily A,
member 4C
4.2 2.85 -1.03 14.48
Ms4a6b 293749 membrane-spanning 4-domains, subfamily A,
member 6B
3.05 1.52. 2.18 3.51
Chaperone ATP binding Protein folding Tor3a 30935 Torsin family 3, member A 2.66 6.12 4.53 19.1





Phagocytic killing Cybb 13058 Cytochrome b-245, beta polypeptide 2.96 1.77 1.18 8.21
Receptor Cd14 12475 CD14 antigen 3.27 1.68 1.76 2.01
(continued on next page)(continued on next page)




Speciﬁc Function Biological Process Gene Symbol Entrez
GeneID
Description 5 dpi 6 dpi 7 dpi 8 dpi
NC Poly-A-polymerase Transcription regulation Parp14 547253 Poly (ADP-ribose) polymerase family, member 14 5.42 6.51 2.71 13.2
NC Parp12 243771 Poly (ADP-ribose) polymerase family, member 12 4.12 4.51 4.31 7.9
Helicase NC BC013672 234311 cDNA sequence BC013672 5.65 4.51 2.33 7.62
BC013672 234311 cDNA sequence BC013672 8.96 11.4 3.86 19.8
Protein transport NC 4930599N23Rik 75379 RIKEN cDNA 4930599N23 gene 2.11 2.95 1.74 2.07
Mitd1 69028 RMIT, microtubule interacting and transport, domain
containing 1
1.8 1.66 1.55 3.17
Kinase NC Mlkl 74568 Mixed lineage kinase domain-like 4.29 4.48 2.3 3.96
DNA binding NC Zbp1 58203 Z-DNA binding protein 1 2.79 2.48 1.96 4.98
Apoptosis Scotin 66940 Scotin 3.49 2.59 3.77 2.69
Receptor Interferon-induced Rtp4 67775 Receptor transporter protein 4 2.75 4.1 2.4 2.64
Protein/nucleic acid
binding
Interferon-induced Trim34 94094 Tripartite motif protein 34 2.47 2.72 2.04 2.72
NC Trim30 20128 Tripartite motif protein 30 3.93 5.54 2.82 8.05
NC Cell proliferation Slfn2 20556 Schlafen 2 3.32 2.51 2.02 5.3
NC NC NC BC006779 229003 cDNA sequence BC006779 2.24 3.67 2.34 3.88
Epsti1 108670 Epithelial stromal interaction 1 (breast) 2.24 4.41 2.89 4.64
D12Ertd647e 52668 DNA segment, Chr 12, ERATO Doi 647, expressed 2.96 3.06 2.24 1.86
Samd9l 209086 Sterile alpha motif domain containing 9-like 4.04 6.67 4.16 13
D14Ertd668e 219132 DNA segment, Chr 14, ERATO Doi 668, expressed 3.56 5.97 3.3 10.4
Rnf213 629974 Ring ﬁnger protein 213 4.19 8.44 3.43 7.04
Phf11 219131 PHD ﬁnger protein 11 9.3 8.5 4.53 22.8
0610037M15Rik 68395 RIKEN cDNA 0610037M15 gene 3.59 6.29 3.07 6.14
9830115L13Rik 319257 RIKEN cDNA 9830115L13 gene 3.14 5.85 8.29 5.27
A630077B13Rik 215900 RIKEN cDNA A630077B13 gene 2.85 1.36 1.32 7.16
C4a 625018 Complement component 4A (Rodgers blood group) 1.73 2.94 2.62 5.25
Gp49a 14727 Glycoprotein 49A 3.95 1.26 1.61 4.59
Drld 114573 Differentially regulated in lymphoid organs and
differentiation
1.87 1.33 1.88 3.54
H2-T17 15032 Histocompatibility 2, T region locus 17 5.46 3.17 1.37 9.83
Rnf213 629974 Ring ﬁnger protein 213 4.2 8.44 3.43 7.05
⁎ Not classiﬁed.
1. Genes with more than one probe had their intensity averaged.
2. Gene functional classiﬁcation was done using NCBI Entrez Gene (www.ncbi.nih.gov) and Gene Ontology (www.geneontology.org) database.
326 J. Bordignon et al. / Virology 377 (2008) 319–329(Tumpey et al., 2007). Mx1, Mx2 and MxA are up-regulated in HUVEC
cells infected with DENV2 (Warke et al., 2003). PBMCs from monkeys
infected with dengue virus type-1 also exhibit up-regulation of Mx1
and Mx2 (Sariol et al., 2007), giving support to our ﬁndings, however,
the potential role of these family gene in dengue virus infection needs
to be better evaluated. Recently, Simmons et al. (2007) demonstrated
that the levels of transcription of 24 genes, including Mx1 and Mx2,
were attenuated in patients with DSS when comparing with patients
with DHF, suggesting an important role of these genes in the severity
of dengue infection.
In this study, genes involved in antigen processing (Psmb8 and
Psmb9, or LMP7 and LMP2), in transportation of antigens to
endoplasmic reticulum (Tap1 and Tap2), and in the presentation of
major histocompatibility complex (MHC) class I and II at the cell
surface were up-regulated. MHC-encoded IFN-γ-inducible low mole-
cular weight proteins (LMP2, 7 and 10) form the immunoproteasome.
This degradative system seems to have different substrate speciﬁcity
than that of a proteasome (Van de Eynde and Morel, 2001; Groettrup
et al.,1996). The immunoproteasomewas observed in neuronal cells in
some neurodegenerative disorders like Huntington's Disease (Diaz-
Hernandez et al., 2003), Amylotropic Lateral Sclerosis (Cheroni et al.,
2005) and Alzheimer's Disease (Mishto et al., 2006). MHC class I levels
are low in the intact CNS and is conﬁned to blood vessels (Gehrmann
et al.,1991,1993; Vass and Lassmann,1990).MHC class II is consistently
found on meningeal macrophages, choroid plexus macrophages and
perivascular cells (Gehrmann et al., 1991, 1993, 1995; Graeber et al.,
1989, 1992; Hickey and Kimura, 1988; Hickey et al., 1992; Vass and
Lassmann, 1990). Additionally, MHC class II seems to be constitutively
expressed on a subpopulation of resident microglia (Streit et al., 1989).
Threemain hypotheses could be raised to explain the expression of
antigen processing and presentation in mice CNS after dengue virus
infection: expression by neuron infected cells; expression by accessory
cells, like microglia, oligodendrocytes and endothelial cells; and ex-pression by inﬁltrated cells, like B cells or monocytes/macrophages
from periphery. Classically, neurons do not participate in antigen
processing and presentation, and are generally incapable of expressing
MHCmolecules in their surface (Gogate et al., 1996; Joly and Oldstone,
1992). However, it was recently demonstrated that during acute
infectionwithmouse hepatitis virus (MHV),MHC class I is expressed in
vivo by neurons, oligodendrocytes, microglia and endothelia, andMHC
class II is expressed only by microglia. These data indicates that
neurons cells have the potential to present antigen to T cells and thus
be damaged by direct antigen-speciﬁc interactions with CD8+ T
lymphocytes (Redwine et al., 2001). Recently, was demonstrated the
expression of LMP genes in murine neuronal cells after IFN-γ treat-
ment (Yang et al., 2006). In contrast, inﬂammatory cytokines (IFN-γ
and TNF-α) can induce the expression ofMHC class II molecules on the
cell surface of astrocytes (Vass and Lassmann, 1990), suggesting that
cytokines produced by infected cells could trigger the gene expression
in surrounding cells. Finally, we previously demonstrated that DENV1
FGA/89-infected animals present mild chronic lymphoystiocitic
leptomeningitis (Bordignon et al., 2007); thus, the up-regulation of
genes involved in antigen processing and presentation that we
detected in our studies could be a result of cell inﬁltration in the CNS
(such as monocytes/macrophages and lymphocytes).
We observed the up-regulation of ISGs (Isg15, Ube1l, Ube2l6 and
Usp18) involved in the ubiquitin-like process, known as protein
ISGylation. Isg15 has an amino-acid sequence with considerable
homology to that of ubiquitin, and is conjugated and deconjuganted
to target proteins through a set of reactions that involve activating
(Ube1l; Yuan and Krug, 2001), conjugating (Ube2l6; Kim et al., 2004)
and deconjugating enzymes (Usp18 or Ubp43) (Malakhov et al., 2002).
Protein ISGylation has been implicated in fetal development and
innate immunity (Rempel et al., 2007; Ritchie et al., 2006). A recent
study demonstrated that mice deﬁcient in Usp18 (deconjugating
enzyme) are resistance to fatal lymphocytic choriomeningitis virus
327J. Bordignon et al. / Virology 377 (2008) 319–329(LCMV) and vesicular stomatitis virus (VSV) infections. Usp18 knock-
out mice have an enhanced interferon-mediated response, which may
underlie the low viral RNA replication efﬁciency and antigen
expression in the brains of infected animals (Ritchie et al., 2006).
Malakhova et al. (2006) demonstrated that Ubp43 (Usp18) binds to the
IFNAR2 receptor subunit, blocking the receptor's interaction with
JAK1, and thus inhibiting JAK1 activity (Malakhova et al., 2006). The
authors showed that Usp18 functions as a negative regulator of the
IFN-mediated response, which is essential for ensuring an appropriate
and controlled cellular response to type I IFN. Conversely, inhibition of
Usp18 enhances the IFN response, presenting a potential alternative
target for antiviral therapies. The role of protein ISGylation in the
antiviral response has recently been demonstrated for inﬂuenza B virus
(Yuan and Krug, 2001), LCMV, VSV (Ritchie et al., 2006), and Sindbis
virus (Lenschow et al., 2005). The expression of genes involved in this
pathway is modulated by viral infection mediated by the Flaviviridae
family, including hepatitis C and DENV1 infection in chimpanzees and
monkeys, respectively, and WNV infection in mice (Bigger et al., 2004;
Sariol et al., 2007; Venter et al., 2005). Recently, Warke et al. (2008)
shows up-regulation of USP18 gene in HUVEC cells, and in human
monocytes and B cells infected with DENV2. Overall, these ﬁndings
suggest that a common pathway is modulated by IFN in response to
virus infection in vertebrate hosts. However, the role of this pathway in
human DENV infections needs to be conﬁrmed in future studies.
Our ﬁndings demonstrate the up-regulation of genes involved in
the complement system, H2-Bf (Complement factor B), C1qb, C1r, C2
and C4 — with mRNA levels increasing 1.4- to 5.8-fold between dpi 5
and dpi 8 — in Swiss mice infected with DENV1 FGA/89 (Table 2;
Fig. 4). The complement system is a family of more than 30 proteins,
including cell surface receptors, which recognize pathogen-associated
molecular patterns (PAMPs), altered self-ligands, or immune com-
plexes (Carroll, 2004). Complement activation was proposed 30 years
ago as a major event in the development of DHF/DSS (Bokisch et al.,
1973). Complement can be activated by non-structural protein NS1
(soluble or cell-associated), and enhanced by anti-NS1 antibodies,
leading to local or systemic generation of anaphylatoxins and terminal
complex SC5b-9. Plasma levels of NS1 and terminal complex SC5b-9,
from 163 patients, correlate with disease severity (Avirutnan et al.,
2006). Similarly, activation of the complement system in dengue virus
infection could contribute to the pathogenesis of vascular leakage in
DHF/DSS (Avirutnan et al., 2006). Mehlhop and Diamond (2006) also
demonstrated an important role for complement activation in pro-
tection and in priming the adaptive immune response to WNV in-
fections. They showed that mice deﬁcient in C1q, C4, factor B or D, and
infected with WNV, had an increased mortality rate, suggesting that
the different activation pathways (classical, lectin and alternative) act
together to limit WNV infection spreading. A deﬁciency in the
alternative pathway led to a delay in splenic clearance and a blunted
T-cell response. Deﬁciencies in the classical and lectin pathways were
associated with decreased splenic infection and deﬁcits in the B- and
T-cell responses to WNV infection in the murine model.
We previously demonstrated that animals infected with DENV1
FGA/89 develop mild chronic lymphoystiocitic leptomeningitis with-
out encephalitis, with complete viral clearance at 30 dpi (Bordignon
et al., 2007). We demonstrated that animals developed a strong innate
immune response, and exhibited an up-regulation of antiviral ISGs
that seems to be responsible in the control of dengue infection in mice
CNS, preventing the death of the animals. Our ﬁndings of changes in
gene expression during DENV1 infection in the mouse CNS are
consistent with recent results obtained by Sariol et al. (2007) in PBMCs
from monkeys infected with DENV1, and by Warke et al. (2008) in
human monocytes, B cells and HUVEC cells infected with DENV2. A
better understanding of innate immunity mechanism acting against
viral infections offers the possibility of new potential strategies for
developing therapies against dengue infection. Indeed, the potential
modulation of innate immunity to improve the antiviral response inan infected host, limiting viral replication and reducing the severity of
disease, may be an effective strategy to ﬁght DENV infection.
Material and methods
Viruses and infection of animals
Virus stocks were ampliﬁed in C6/36 cells and puriﬁed in a sucrose
gradient as described by Gould and Clegg (1985). Mock was prepared
from non-infected C6/36 cell supernatants at the same time points and
processed following the sameprotocols. Virus titerwasdeterminedby the
focus-formingunit technique inC6/36cells (ffuC636), describedbyDèspres
et al. (1993). The FGA/89 viral strain was kindly supplied by Dr. Philippe
Desprès, from theUnité des InteractionsMoléculares Flavivirus-Hôtes at the
Pasteur Institute, Paris, France. FGA/89 was isolated in South America in
1989 from a patient with DF. Dèspres et al. (1998) had shown that this is
an avirulent strain for mice, however, recently we demonstrated that
although mice survive without signals of encephalitis, this strain causes
leptomeningitis in infected mice (Bordignon et al., 2007).
To avoid bias in the experiments, animals used in the study were
grouped together after birth (from different females), assorted and
separated into two groups of 30 newborn animals. Forty eight hours
after birth, Swiss mice underwent intracerebral (IC) inoculation with
8000 ffuC636 of DENV1 FGA/89 or weremock-infected. At days ﬁve, six,
seven and eight post-infection (dpi), ﬁve animals from both the mock-
infected and FGA/89-infected groups were killed, and their encepha-
lus was retrieved and pooled for biological and gene expression
analyses. Animal experiments were approved by the ethical commit-
tee on animal experimentation of the Oswaldo Cruz Foundation (CEP/
FIOCRUZ 264/05) and the Federal University of Paraná (CEP/UFPR
23075.002348/2007-14).
Viral load in the CNS of infected mice
We extracted RNA from pooled brain tissues of mock and DENV1-
infected animals usingRNeasyMiniKit (Qiagen) followingmanufactures
instructions. Viral RNA load was determined by quantitative RT-PCR
(qRT-PCR), as described by Poersch et al. (2005). The qRT-PCR curves
were normalized using murine glyceraldeyde-3-phosphate dehydro-
genase (Gapdh), as described previously (Bordignon et al., 2007).
RNA samples and microarrays hybridization
RNA obtained from the brains of infected andmock-infected animals
was ampliﬁed in vitro using the Amino Allyl MessageAmp™ aRNA
Ampliﬁcation kit (Ambion Inc., Austin, TX, USA) according to manufac-
turer's instructions. The quantity and quality of the ampliﬁed RNA
(aRNA) were evaluated by spectrophotometry at 260/280 nm. Before
hybridization experiments, microarrays were re-hydrated with 3× SSC/
0.2% sodiumdodecyl sulfate (SDS) and cross-linkedwith65mJunderUV
irradiation. Microarrays were washed with distilled water and 95%
ethanol, and then blocked with anhydride succinic solution. This pre-
treatment blocks amines from binding the microarrays prior to
hybridization, reducing the background and providing a better distribu-
tion of DNA across the surface of the spot. The murine microarray —
produced in the Virginia Commonwealth University (USA) — contains
38,467 mouse exonic evidence-based oligonucleotide (MEEBO) 70-mer
probes, targeting 35,302 mouse genes and 3482 controls.
For microarray experiments, aRNA (3 μg) was reverse transcribed
with 2 nmol of random hexamers (Invitrogen), 25 nmol of each dNTP,
2 μl of reverse transcriptase (ImProm-II™ Reverse Transcriptase/
Promega) and 60 U of RNAse OUT™ (Invitrogen) at 42 °C for 2 h. RNA
was denatured with 0.03 N NaOH at 70 °C for 10 min and the pH of
solutionwas neutralizedwith 0.03 N HCl. After awash stepwith water
using Microcon 30, the volume was adjusted to 22 μl and the material
was used to synthesize a second-strand DNA at 37 °C for 2 h using
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polymerase (BioPrime DNA Labeling System Kit), 6 nmol of dATPs,
dGTPs and dTTPs, 3 nmol of dCTPs and 2 nmol of dCTP-Cy3 or dCTP-
Cy5. Finally, the samples were washed twice with DEPC water using
Microcon 30 ﬁlters (Amicon) and diluted in hybridization solution (5×
SSC, 4.2× Denhardt's solution, 0.21 mg/ml ssDNA, 0.42% SDS and 42%
formamide) to a ﬁnal volume of 120 μl. They were then heat-
denatured and loaded using a workstation GeneTAC HybStation
(PerkinElmer) for hybridization at 42 °C for 16 h. The arrays were
washed twice for 5 minwith a solution containing 0.01% SDS and 0.5×
SSC, and a further two times with 0.06×SSC solution. Finally,
ﬂuorescence was measured in a scanner (Array Express, PerkinElmer)
at 550 nm and 649 nm for Cy3 and Cy5, respectively.
Data analysis
Microarray images were analyzed with the Spot software (Beare
and Buckley, 2004). Background extraction and data normalization
were performed by the limma software (Smith, 2004). Single channel
intensity from all technical replicates (hybridizations) for each day of
mock and FGA/89 samples were averaged and differential expression
was assessed by means of a two class unpaired SAM test (Tusher et al.,
2001), using two-fold change and 1% FDR (false discovery rate) as
thresholds. Aiming to increase the stringency of the differential
expression attribution, samples collected on the different days were
considered as biological replication unity. As a consequence, we loose
the ability to select point-speciﬁc differences, but increase the power
to conﬁdently select genes that were changed in a more general trend,
what is more related to the approach used, namely a whole tissue and
late days analysis.
Selected genes from the microarray data were also analyzed using
the Ingenuity Pathways Analysis software (IPA; Ingenuity Systems®,
www.ingenuity.com; Redwood City, CA, USA). Ingenuity Pathways
Analysis Knowledge Base is a curate database, constructed based on
scientiﬁc evidence obtained from hundreds of thousands of journal
articles, textbooks, and other data sources. A list of all genes
modulated obtained by microarray experiments were analyzed by
IPA software, to deﬁne which well-characterized cell signaling and
metabolic pathways are most relevant during DENV infection in mice
CNS. The signiﬁcance (p-values) of the association between the
dataset and the canonical pathway was measured by comparing the
number of user-speciﬁed genes of interest participating in a given
pathway, relative to the total number of occurrence of these genes in
all pathway annotations, stored in Ingenuity Pathways Knowledge
Base. Fisher's exact test was used to calculate a p-value determining
the probability that the association between the genes in the dataset
and the canonical pathway is explained by chance only.
Relative quantiﬁcation of mRNA levels by quantitative PCR (qPCR)
Messenger RNA (mRNA) levels from 10 genes (Stat1, Irf7, Irf1, Iﬁt3,
Gbp4, Mx1, Oas1b, Ccl5, Psmb8 and Tap1) were determined by qPCR.
RNA samples isolated from dengue- and mock-infected mice brain
tissues were reverse transcribed using ImProm-II™ (Promega,
Madison, WI) and oligo-dT primers (20 μM) following the manufac-
turer's protocol. The resulting cDNAswere ampliﬁed by PCRwith SYBR
Green master mix (Applied Biosystems, Inc.) in an ABI PRISM 7000
Sequence Detection System (Applied Biosystems, Inc.) The following
cycle was used for ampliﬁcation: 50 °C for 2 min, 96 °C for 10 min,
followed by 40 cycles of 96 °C for 15 s, 60 °C for 30 s, and 72 °C for
1 min (primers sequences are showed in Table 1). Melting curves were
used to verify product speciﬁcity. The murine housekeeping gene
encoding Gapdh was also included, for normalization of mRNA levels
as described previously (Bordignon et al., 2007). Levels of mRNA for
each selected gene were recorded as fold increase induced by dengue
virus infection in the CNS of mice. Fold increase was the amount ofmRNA for each gene from DENV1-infected animal tissues divided by
amount of mRNA frommock-infected animal tissues taken at the same
time points.
Immunohistochemistry
Mice fromDENV1 FGA/89-infected andmock-infected groupswere
killed at 10 dpi; brain tissues were collected and ﬁxed in 10% buffered
formalin. Fixed tissues were parafﬁn embedded, sectioned, and
stained with a ﬂavivirus group-speciﬁc monoclonal antibody 4G2
(1:100). Goat anti-rat immunoglobulin conjugated to peroxidase-
labeled dextran polymer (Envision+/Peroxidase, DakoCytomation®)
was used as secondary antibody, and liquid DAB (DakoCytomation®)
was used for visualization. Antigen recovery was performed using the
ImmunoRetriver Bio SB® Kit.
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